Fundraising Fox
/Companies
Sign in

TellBio

Andover, US · Founded 2019 · Delaware corporation

Find your way into TellBio

Sign up to see every warm intro you have to TellBio

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the TellBio team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

TellBio is a biotechnology company founded by leading cancer researchers and clinicians from Harvard Medical School and Massachusetts General Hospital. The company focuses on oncology research and development, leveraging circulating tumor cell (CTC) technology and biomedical engineering.

AI & Machine LearningBiotechHealthtechMedical Devices

Founders & leadership

TellBio was founded in 2019 by Daniel Haber, Mehmet Toner, David Ting, Shyamala Maheswaran, and Ravi Kapur.

DH
Daniel HaberFounder
MT
Mehmet TonerFounder
DTDavid Ting
David TingFounder
SM
Shyamala MaheswaranFounder
RK
Ravi KapurFounder
PGPRITESH GANDHI
PRITESH GANDHIExecutive

Board

GC
GARY CROCKERBoard director
RP
Richard PetersFounder & Executive Chairman
BP
BERNARD PETERSBoard director

Reported raises · per SEC filings

Form D private placements

$11M disclosed across 5 rounds · 2019–2024

▶$1MraisedMar 2026 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • GARY CROCKERDirector
  • RICHARD PETERSExecutive Officer, Director
  • BERNARD PETERSDirector
Offering amount
$1M
Amount sold
$1M
First sale
Sep 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.2MraisedJul 2024 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • RICHARD PETERSDirector
  • BERNARD PETERSDirector
  • PRITESH GANDHIExecutive Officer, Director
  • GARY CROCKERDirector
Offering amount
$1.2M
Amount sold
$1.2M
First sale
Jun 2024
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.3MraisedMar 2023 · 23 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Richard PetersDirector
  • Pritesh GandhiExecutive Officer, Director
  • Gary CrockerDirector
  • Bernard PetersDirector
Offering amount
$2.5M
Amount sold
$2.3M
First sale
Feb 2023
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5MraisedMar 2021 · 29 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Richard PetersExecutive Officer, Director
Offering amount
$5M
Amount sold
$5M
First sale
Mar 2021
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.5MraisedOct 2019 · 19 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Richard PetersExecutive Officer, Director
Offering amount
$1.5M
Amount sold
$1.5M
First sale
Sep 2019
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 3

EvolveImmune TherapeuticsEvolveImmune develops immunotherapy treatments for cancer patients. The company focuses on discovering and developing novel biotherapeutics in immuno-oncology and related immune-mediated diseases.
Mission BioCapital Platinum Program Holdings LLCMission BioCapital is a venture capital firm that invests in early-stage life science companies, from therapeutics and drug discovery to biotech tools and diagnostics. The firm provides capital, operational support, and lab infrastructure through its MBC BioLabs co-working spaces to help scientific entrepreneurs launch and scale biotech startups.
GentiBioGentiBio develops engineered regulatory T-cell (EngTreg) therapies designed to reset the immune system and treat autoimmune and acute inflammatory diseases. The company builds autologous and allogeneic Treg platforms as an alternative to systemic immune-suppressive therapies.

Companies working in the same space as TellBio.

In the news

TellBio Unveils Next-Generation Liquid Biopsy Platform Focused on Early Detection and Treatment of Cancer - TellBiotellbio.com · May 2021

Frequently asked questions

What does TellBio do?
TellBio is a biotechnology company founded by leading cancer researchers and clinicians from Harvard Medical School and Massachusetts General Hospital. The company focuses on oncology research and development, leveraging circulating tumor cell (CTC) technology and biomedical engineering.
Who founded TellBio?
TellBio was founded by Daniel Haber, Mehmet Toner, David Ting, Shyamala Maheswaran, Ravi Kapur in 2019.
How much funding has TellBio raised?
TellBio has disclosed $11M raised across 5 rounds.
Where is TellBio headquartered?
TellBio is headquartered in Andover, US.